Related Experiment Video
Updated: Apr 17, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Successful desensitization of a patient with rituximab hypersensitivity
Pinar Ataca1, Erden Atilla1, Resat Kendir2
1Department of Hematology, Ankara University, Cebeci, 06590 Ankara, Turkey.
Abstract:
Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Desensitization and Tachyphylaxis
Hypersensitivity Reactions: Immune-Complex Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Allergic Reactions: Anaphylaxis

